- Home
- OPFI vs SLP Comparison
OPFI vs SLP Comparison
Compare OPFI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- SLP
- Stock Information
- Founded
- OPFI 2009
- SLP 1996
- Country
- OPFI United States
- SLP United States
- Employees
- OPFI N/A
- SLP N/A
- Industry
- OPFI Finance: Consumer Services
- SLP EDP Services
- Sector
- OPFI Finance
- SLP Technology
- Exchange
- OPFI Nasdaq
- SLP Nasdaq
- Market Cap
- OPFI 288.7M
- SLP 322.4M
- IPO Year
- OPFI N/A
- SLP 1997
- Fundamental
- Price
- OPFI $9.71
- SLP $17.31
- Analyst Decision
- OPFI Buy
- SLP Buy
- Analyst Count
- OPFI 2
- SLP 7
- Target Price
- OPFI $11.75
- SLP $26.80
- AVG Volume (30 Days)
- OPFI 679.6K
- SLP 396.3K
- Earning Date
- OPFI 10-29-2025
- SLP 01-06-2026
- Dividend Yield
- OPFI 2.56%
- SLP N/A
- EPS Growth
- OPFI N/A
- SLP N/A
- EPS
- OPFI 0.14
- SLP N/A
- Revenue
- OPFI $335,423,000.00
- SLP $80,383,000.00
- Revenue This Year
- OPFI $119.75
- SLP $13.67
- Revenue Next Year
- OPFI $10.98
- SLP $1.50
- P/E Ratio
- OPFI $71.14
- SLP N/A
- Revenue Growth
- OPFI 28.69
- SLP 20.01
- 52 Week Low
- OPFI $6.65
- SLP $12.39
- 52 Week High
- OPFI $17.73
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- OPFI 49.91
- SLP 54.91
- Support Level
- OPFI $9.04
- SLP $16.62
- Resistance Level
- OPFI $9.76
- SLP $17.64
- Average True Range (ATR)
- OPFI 0.40
- SLP 0.65
- MACD
- OPFI 0.02
- SLP -0.05
- Stochastic Oscillator
- OPFI 56.61
- SLP 70.70
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.